MGI To File Saforis NDA For Oral Mucositis By October
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to file the fast-track NDA based on the results of one Phase III trial. A second trial will be initiated after the filing in order to expand the market potential and support a European filing, MGI says.
You may also be interested in...
MGI’s Oral Mucositis Therapy Saforis NDA Submitted
The firm had planned to file the application for glutamine in the third quarter of 2005.
MGI’s Oral Mucositis Therapy Saforis NDA Submitted
The firm had planned to file the application for glutamine in the third quarter of 2005.
Amgen Kepivance Launch Under Way At Price Of $1,375 Per Dose
Mucositis therapy will have an initial market of less than $50 mil. for first approved indication, but potential for use in broader cancer market would be $3 bil. opportunity. Kepivance will help Amgen build on position as number one oncology company in U.S., although Amgen is cautioning investors to expect slower growth in 2005 in light of reimbursement climate.